Two Very Different Businesses Behind One Keyword

"Contact lens manufacturer" covers two businesses that share almost nothing except the product category. Confusing them is the single most common reason a lens manufacturing plan gets declined, because the founder writes the operating model of one and the capital ask of the other.

The first is high-volume cast moulding. Liquid monomer is injected between two single-use moulds, polymerised, demoulded and hydrated in aerated water, then inspected and blister-packed. Output is measured in millions of lenses a year, the SKU count is small, and the unit price is fractions of a dollar. It is a plastics-processing business with an ophthalmic label on it. The economics only close at enormous volume, and the shelf space that volume needs is already taken: Johnson & Johnson Vision Care alone held more than 12% of the global market in 2025, and the next five players held 35% between them (Global Market Insights, 2025). In North America the concentration is starker still: the top five companies accounted for 88.7% of the market, with Johnson & Johnson at 29.8% on its own (Global Market Insights, 2025).

The second is a lathe-cut specialty or custom lab. A hard, non-hydrated button of lens material is mounted on a spinning shaft, typically around 6,000 rpm, and a computer-controlled diamond tool cuts the front and back surfaces, after which the lens is polished, hydrated where the material requires it, and inspected individually (1-800 Contacts, Eye Society). Every lens is effectively a batch of one, cut to a prescription and a corneal shape that arrived that morning. Output is measured in thousands of lenses a year, the SKU count is functionally infinite, and the unit price runs from double to low triple digits. It is a precision machining business wrapped in a quality system.

Spin casting sits between the two: liquid monomer is injected into a spinning mould, spread across the mould face by rotation, cured under ultraviolet light, then edge-buffed, polished and hydrated in a sterile bath. It mass-produces, but with less design freedom than lathing and less throughput than full cast moulding.

For a first-time founder without an existing distribution relationship, the specialty lab is the route that actually funds. It is also the route where the market data is moving: the orthokeratology segment alone is tracked at roughly $2.75 billion in 2025 heading past $6 billion by 2034 (Grand View Research), driven almost entirely by paediatric myopia management rather than adult vision correction. The rest of this guide prices the specialty route in detail and flags where the moulding route diverges, so your plan commits to one and defends it.

If your concept is closer to retail or distribution than to production, start with our contact lenses business plan template instead, and if you are planning a broader ophthalmic product range, the ophthalmic goods manufacturer template is the better fit.

Equipment & Cleanroom Checklist With Real Prices

Most guides tell you to "invest in lathes, polishing machines and testing apparatus," which is useless to a lender. Below is the equipment list for a two-lathe specialty lab, with the price bands you should defend in your capital schedule. Quote every line in your plan as a range with a named class of machine, not a single number.

Production equipment

• CNC diamond-turning optical lathe: $420,000–$680,000 new for an Optoform-class machine from Precitech; $140,000–$260,000 for a refurbished unit with a current controller. Budget two, because a single lathe means a single point of failure for every open order in the lab.
• Second-operation stations: blocking, polishing and edging equipment, $45,000–$110,000 for the set. Edge quality is the most common comfort complaint and the most common remake trigger, so do not economise here.
• Hydration and extraction line (soft materials only): $60,000–$180,000. Soft lenses take their final geometry from hydration, absorbing roughly 30% to 80% of their weight in water depending on material, so this step is dimensional control, not just a rinse.
• Sterilisation and packaging: autoclave plus blister or vial sealing, $55,000–$165,000 depending on whether you validate in-house or use a contract steriliser.
• Tooling and diamond consumables: $18,000–$40,000 opening set, then a recurring line. Diamond tool wear shows up as a surface-quality drift long before it shows up as a failure, which is why the metrology below is non-negotiable.

Metrology and quality control

• Non-contact interferometric lens mapper: $45,000–$120,000. Instruments from Rotlex map the full lens surface rather than sampling points, which is what ortho-K and multifocal designs require to pass audit.
• Radiuscope and keratometer bench: $8,000–$22,000.
• Wet-cell diameter and sagittal-depth gauge: $9,000–$28,000, essential for soft and hybrid lenses measured in the hydrated state.
• Centre-thickness and power verification: $8,000–$20,000.
• Environmental monitoring: particle counters, differential pressure logging and viable-air sampling, $14,000–$38,000 plus an annual requalification cost.

The cleanroom is a milestone, not a line item

ISO Class 7 cleanroom construction runs $400 to $650 per square foot in 2026, and a 5,000 square foot stick-built room typically takes 9 to 14 months from design start to validated handover. Modular systems compress construction by 25% to 40%, with a 5,000 square foot modular install typically landing in 3 to 5 months once the site is ready (Terrapin Consulting Group, 2026). For a 1,900 square foot specialty lab that is roughly $760,000 to $1.24 million, and it is the critical path for your entire launch timeline. Put the validated-handover date on your Gantt chart and hang the 510(k) submission, the first validation batch and the first invoice off it.

Equipment you should not buy

General optical milling machines listed on marketplace sites at around $2,000 are not validated contact lens systems. They lack lens-specific toolpath libraries, hydration control and any medical-grade qualification history, which means you cannot use them to produce a device you intend to sell. They are fine for R&D geometry experiments and worthless for production. Listing one in a capital schedule tells a lender you have not spoken to a lathe vendor.

What It Costs to Stand Up a Lens Plant

A two-lathe specialty lab reaching its first validated shipment costs $380,000 to $1.2 million in the United States, or £290,000 to £920,000 in the United Kingdom, excluding the building shell. The spread is almost entirely cleanroom size and whether you buy lathes new or refurbished. A full cast-moulding line is a different order of magnitude: $1.8 million to $2.5 million for a turnkey installation including cleanroom HVAC interface and production-system integration, and that is before working capital.

Capital and pre-revenue cost stack

• Lathes, second-operation and sterilisation equipment: $520,000–$955,000 new, or $230,000–$440,000 with refurbished lathes
• ISO Class 7 modular cleanroom, 1,500–2,500 sq ft: $600,000–$1,625,000
• Metrology suite: $70,000–$190,000
• ISO 13485 quality system build and initial certification: $22,000–$83,000
• FDA 510(k) preparation per lens family: $60,000–$220,000 including biocompatibility and sterilisation validation
• Opening material inventory (button blanks and monomer): $30,000–$95,000
• Lab software, eQMS and practitioner order portal: $18,000–$60,000 in year one
• Working capital through a nine-month pre-revenue validation window: $180,000–$450,000

That nine-month window is the line most plans omit and the line that kills most of them. Between cleanroom handover and your first invoiceable lens sit installation qualification, operational qualification, performance qualification, process validation batches and, in the US, the wait for a substantial-equivalence letter. You are paying technicians, rent and utilities throughout with nothing to bill. Our market research and content service builds this as an explicit pre-revenue phase in the model rather than a footnote.

Funding routes that match the asset profile

Lens manufacturing is unusual among small manufacturers because the asset base is both expensive and genuinely collateralisable. That argues for splitting the raise rather than taking one instrument.

In the United States, NAICS code 339115 Ophthalmic Goods Manufacturing carries an SBA size standard of 1,000 employees as of March 2023 (SBA Table of Small Business Size Standards), so effectively every new lens maker qualifies as a small business for both the 7(a) and 504 programmes. The 7(a) programme remains large, with 70,242 loans worth a combined $31.1 billion approved in FY2024 (SBA 7(a) programme data, FY2024), but it is the wrong instrument for a cleanroom on its own. The structure that gets approved looks like this:

• SBA 504 debenture against the cleanroom build and the lathes, taking advantage of long amortisation on fixed assets with a usable economic life measured in decades
• SBA 7(a) sitting over the top for working capital, the quality system build and the regulatory spend, which no asset-backed lender will fund
• Equipment finance or sale-and-leaseback on the second lathe, which both reduces the day-one ask and gives you a documented machine valuation
• Founder equity of 10% to 20%, which SBA lenders will look for on a project of this capital intensity

In the UK, the Start Up Loans scheme caps at £25,000 per founder, which is immaterial against a cleanroom. Realistic UK routes are Innovate UK grant funding for a genuinely novel lens design or material, EIS-qualifying equity, and asset finance against the lathes. Either side of the Atlantic, the question a credit committee asks is not "what is your margin" but "at what unit volume do you cover fixed cost, and what evidence supports reaching it." Put that number on page one. Our bespoke business plan service builds the break-even volume as the headline of the financial summary for exactly this reason.

Material Houses, Lathe Makers & Metrology Vendors

You do not formulate your own lens material. Almost nobody does. You buy qualified polymer from a material house, and their master file plus biocompatibility data becomes part of your regulatory submission, which makes the material supplier a regulatory decision disguised as a procurement decision. It belongs in your operations plan with a named vendor, not a placeholder.

Rigid gas permeable and scleral materials

• Contamac: founded in Britain in 1987 and now one of the two reference material houses globally. Its Optimum range runs Optimum Classic, Optimum Comfort, Optimum Extra and Optimum Extreme across an ascending oxygen-permeability ladder (Contamac, In Contact Chapter 6). Specifying the full ladder rather than one grade lets a fitting practice keep a difficult patient with you rather than sending the order elsewhere.
• Boston materials from Bausch + Lomb: the Boston ES, EO, XO and XO2 family. The published GP Lens Manufacturing Guide also covers calibration blanks for lathe setup, which matters more than it sounds: your installation qualification needs documented cuts on known material before you touch a patient order (Boston Lens Materials, GP Lens Manufacturing Guide).
• Paragon Vision Sciences: an RGP material producer that also owns ortho-K designs, which makes it a supplier and a competitor at once. Read the licensing terms before you build a myopia-management product line on their material.
• Benz R&D: a United States hydrogel and silicone hydrogel monomer house, the usual starting point if your product road map includes custom soft lenses alongside rigid work.

Equipment and instrumentation

• Precitech (AMETEK): Optoform series diamond-turning lathes, the machines most specialty labs run. Ask specifically about toolpath libraries for scleral and ortho-K geometries; the machine without the library is a very expensive paperweight.
• DAC International: lathes, polishers and blocking equipment aimed at gas permeable production, and the usual second quote against Precitech.
• Rotlex: non-contact interferometric mapping. Their ortho-K quality control documentation is the clearest public explanation of why point-sampling metrology fails on reverse geometry designs.
• Optimec: wet-cell instruments for soft lens diameter and sagittal depth in the hydrated state.

Benchmark your material menu against the labs you will compete with

Before you finalise a material list, read the published matrices of established labs. Valley Contax of Springfield, Oregon publishes its gas permeable material range openly, and comparing yours against theirs will show up gaps a practitioner would notice in the first month. Do the same with Art Optical Contact Lens of Grand Rapids, Michigan, which has been partnering with practitioners since 1958 and is about as good a benchmark for a specialty lab's product breadth as exists.

Name every supplier with its location and the specific grade or model you intend to qualify. A single-source material with no named alternate is a supply-chain risk a lender will raise; a named primary with a qualified alternate closes that question before it is asked.

Device Approval: FDA, UKCA and CDSCO

Contact lenses are regulated medical devices in every meaningful market. This is the section where competing templates write one sentence about "regulatory compliance" and move on, and it is the section that determines whether your launch date is credible. Price it, date it, and name the submission.

United States

Most soft, rigid gas permeable and hybrid lenses are Class II devices requiring 510(k) premarket notification, which must demonstrate substantial equivalence to a legally marketed predicate device. You cannot commercially distribute until the FDA issues a substantial-equivalence letter (FDA, Overview of Device Regulation).

• Establishment registration renewed annually, and every lens type separately listed in the FDA device database (Registrar Corp, FDA compliance for prescription contact lenses)
• 510(k) content: device description and intended use, substantial-equivalence comparison against the predicate, performance testing, biocompatibility and sterilisation validation, labelling, instructions for use, and a risk analysis
• Quality System Regulation, 21 CFR 820: in place before the first commercial lens, with inspection exposure from day one
• Medical Device Reporting: complaint handling and adverse-event reporting as a standing process, with named ownership in your org chart
• Budget and timeline: $60,000–$220,000 per lens family all-in, typically 6–12 months from submission to clearance. One submission does not cover a whole range, so plan a submission sequence, not a single event

One trap worth naming: non-corrective cosmetic and decorative lenses are regulated as medical devices in the United States too (Registrar Corp, cosmetic and decorative contact lenses). Founders planning a fashion-lens brand routinely model it as a cosmetics launch and discover the full Class II burden after they have committed to a launch date.

United Kingdom

Great Britain runs on the Medical Devices Regulations 2002 (UK MDR) with UKCA marking. The manufacturer completes a conformity assessment with a UK Approved Body, affixes the UKCA mark, appoints a UK Responsible Person where required, and registers the device with the MHRA in DORS before placing it on the market (GOV.UK, Regulating medical devices in the UK).

• Conformity assessment: £25,000–£90,000 for the initial assessment plus annual surveillance, and 9–18 months in practice once Approved Body queue time is counted
• MHRA DORS registration completed before market placement
• UK Responsible Person: required for non-UK manufacturers, and the UKRP name and address must appear on the label
• Labelling: a UKCA, CE or CE UKNI mark is required on all ophthalmic products covered by the regulations, with custom-made devices excepted (GOV.UK, Legal requirements for specific medical devices)

That custom-made exception is strategically important and almost never discussed. A genuinely patient-specific lens, prescribed by a named practitioner for a named patient, follows the custom-made device route rather than carrying a UKCA mark. It is not a loophole, because you still need a quality system, documentation and a declaration, but it changes the sequencing of a UK launch materially, and it is a defensible reason for a UK specialty lab to begin with bespoke scleral work before putting a catalogue design through full conformity assessment. Get that opinion in writing from a regulatory consultant before you build a plan on it.

India

India is the third jurisdiction worth putting in a lens plan, because it is where export-minded founders aim and because the fee schedule is published. Contact lenses are Class B ophthalmic devices under the Medical Device Rules 2017 (CDSCO registration for ophthalmic medical devices).

• Domestic manufacture: a Form MD-5 manufacturing licence, applied for on Form MD-3 to the State Licensing Authority, at ₹5,000 per site plus ₹500 per distinct device
• Import into India: a Form MD-15 import licence, applied for on Form MD-14 to the Central Licensing Authority, with a Class B government fee of US$2,000 per site plus US$1,000 per product
• Retention: a retention fee is due every five years to keep the licence live

The quality system underneath all three

ISO 13485:2016 is the spine that all three routes hang from. Certification takes 6 to 18 months, typically 6 to 12, and for an organisation under 50 staff the initial cost runs $22,000 to $83,000 covering gap analysis, QMS implementation, consultant fees, employee training and certification-body fees (MedDeviceGuide, ISO 13485 cost and timeline guide, 2026; Greenlight Guru, ISO 13485 certification timeline). Start it the month you order the lathes, not the month before your audit. Running the QMS on an eQMS platform rather than a shared drive is worth the subscription for one reason: design history file traceability from a patient order through to a specific diamond tool and a specific material lot is what an inspector asks for, and reconstructing it from spreadsheets afterwards is not realistic.

Unit Economics and Why Remake Rate Decides Everything

Specialty lenses do not invoice to patients. They invoice to the fitting practice, which marks up and bills the patient alongside a professional fitting fee. That single fact determines the whole commercial model: your customer count is in the hundreds of practices, not the hundreds of thousands of consumers, and your sales motion is clinical education rather than advertising.

Scleral and custom rigid lenses wholesale to the practice at roughly $90 to $350 per lens at low volume, with ortho-K pairs sitting at the upper end of that band and custom soft lenses lower. Headline gross margin on lathe work reads well at 58% to 72% before remakes. Net margin lands between 12% and 22% once quality-system upkeep, cleanroom overhead, surveillance audits and warranty remakes are absorbed.

The metric nobody models: remake rate

Specialty lens fitting is iterative. The first lens off a diagnostic fit frequently needs a geometry change, and lab warranty terms almost universally cover those remakes free for a defined window because that is what it takes to win a practice's loyalty. A remake consumes a full production slot, a full button of material and a full inspection cycle, and invoices nothing.

Run the arithmetic. At a 25% first-fit remake rate you need 1.33 production slots per invoiced lens. Your lathe capacity, your technician hours and your material consumption are all 33% higher than your revenue line implies. On a 65% headline gross margin that drags the effective figure down by roughly 14 percentage points, to the low fifties. A lab that drives its remake rate from 25% to 14% through better diagnostic-set design and better practitioner training has effectively added six points of gross margin without touching price, and that, not a price increase, is the operational thesis a specialty lens plan should be built around.

Worked example: a two-lathe lab in year two and year three

A two-lathe specialty lab in its second full year ships 1,400 invoiced lenses at a $165 blended wholesale price, which is $231,000 of lens revenue. Add $34,000 of diagnostic-set sales and fitting consumables to practices and total revenue is $265,000.

• Direct materials and consumables: $41,000 (inflated by a 25% remake rate)
• Two lathe technicians plus a part-time QA lead, fully loaded: $186,000
• Cleanroom lease, utilities, requalification and notified-body surveillance: $96,000
• Operating result: a loss of roughly $58,000

The same cost base at 3,600 invoiced lenses produces $628,000 of lens revenue against materials of about $105,000, one additional technician, and essentially unchanged facility cost, producing roughly $118,000 of operating profit. Break-even for this configuration sits at 2,300 to 2,700 invoiced lenses a year.

That is the whole business in one paragraph. Fixed cost is enormous relative to variable cost, so the plan is not a margin story, it is a volume-ramp story. A lender reading your model wants to see how many fitting practices you need on the books to hit 2,500 lenses, what the average practice orders per month, and what your evidence is for the acquisition rate. If you cannot answer those three questions the forecast is decoration.

Secondary revenue that improves the ramp

• Diagnostic fitting sets placed with practices, sold or consigned. A set in a practice is the single strongest predictor of recurring orders, and the consignment version is effectively customer acquisition cost booked as inventory.
• Contract and private-label lathe work for other labs during spare capacity, which converts idle machine hours into contribution at a lower margin but near-zero acquisition cost.
• Design licensing once a geometry has clinical data behind it, the route by which several specialty names became suppliers to their own competitors.
• Practitioner certification programmes, charged or free, which cut your remake rate and lock in the fitter, hitting the revenue and cost side at once.

Market Size, Concentration and Where the Growth Sits

Quote a market size in your plan and an experienced reader will immediately check whether you understand what the number covers. Published estimates for the global contact lens market diverge by a factor of nearly three, and the reason is scope: some houses count only finished lenses at manufacturer revenue, others include care solutions, accessories and retail margin.

• $13.408 billion in 2025 rising to $18.537 billion by 2030 at a 6.69% CAGR (Knowledge Sourcing Intelligence)
• $12.0 billion in 2025 rising to $16.2 billion by 2033 at a 3.9% CAGR (Grand View Research)
• $22.44 billion in 2024 rising to $35.66 billion by 2030 at an 8.03% CAGR (TechSci Research)
• $20.24 billion in 2024 rising to $33.80 billion by 2030 at an 8.9% CAGR (Ken Research)

Do not pick the biggest number. State your source, state what it includes, then cut it down to the slice you can sell into. A specialty lab in the US Northeast is not addressing a $13 billion market; it is addressing the specialty lens spend of perhaps 400 fitting practices within a two-day shipping radius. That narrower figure is both more credible and more useful, and it is what our research and content package is built to produce.

Concentration is the strategic fact, not the growth rate

Every forecast above agrees the market grows. None of that growth is available to a new entrant in the stock-lens aisle. Alcon, CooperVision and Johnson & Johnson together hold more than 65% of the soft lens segment (Global Market Insights, 2025), and in North America five companies hold 88.7% of everything. Those five own the optical chain contracts, the e-commerce relationships and the practitioner rebate structures. A plan that proposes to win a share of that volume on price alone will be read as naive.

The parts of the category that are both growing and fragmented are specialty: scleral lenses for irregular corneas and ocular surface disease, orthokeratology for paediatric myopia control, and custom soft designs for high astigmatism and presbyopia. The named leaders in scleral are a genuinely mixed field: Visionary Optics, ABB Optical Group, EssilorLuxottica, Bausch + Lomb and Art Optical Contact Lens (Mordor Intelligence, scleral lens companies), with two independents sitting alongside two global groups. That mix is what a winnable market looks like, and it is why your plan should argue from segment structure rather than from headline CAGR.

Estimates for ortho-K specifically run from roughly $2.75 billion in 2025 heading past $6 billion by 2034 (Grand View Research) down to a $1.72 billion base reaching $3.18 billion by 2034 at a 7.2% CAGR (Data Insights Reports). Cite the lower one. A plan that uses conservative figures and still works is far stronger than a plan that needs the optimistic figure to clear its hurdle rate.

Who you are actually competing with

Name real labs in your competitive section, with what makes each one hard to displace:

• Art Optical Contact Lens, Inc. (Grand Rapids, Michigan): partnering with practitioners since 1958, and the breadth of its specialty catalogue is the benchmark
• Blanchard Contact Lenses: supplying custom RGP lenses since its founding in 1986, with a scleral specialism
• Valley Contax (Springfield, Oregon): a focused custom GP and scleral lab with a published material matrix
• Visionary Optics: the Europa Tangent scleral uses a tangential landing-zone angle aimed at stability, comfort and centration, which is a design-led rather than price-led position
• BostonSight: scleral designs that incorporate corneal topographic measurement to correct higher-order aberrations
• ABB Optical Group: manufactures and distributes specialty and ortho-K lenses and is also one of the five companies holding North American share, so it competes at both ends
• UltraVision: a UK specialty maker, and the realistic comparison point for a British entrant
• Menicon: vertically integrated from material through finished lens, and one of the five global players holding 35% between them

Notice what is not on that list: price. None of these labs win on being cheapest. They win on design library depth, turnaround time, warranty generosity and the quality of their practitioner support. Price your lenses accordingly and build the plan around those four levers.

Seven Mistakes That Sink Lens Manufacturing Plans

These are the patterns we see most often when a founder brings us a lens manufacturing plan that has already been declined once.

• Writing the specialty lab's operating model with the moulding plant's capital ask. A plan that describes batch-of-one custom work and then asks for $2.4 million of turnkey moulding line reads as if two documents were stapled together. Pick a route in the executive summary and stay in it.
• Forecasting with no remake line. If your model has lenses produced equal to lenses invoiced, you have assumed a 0% warranty remake rate. No specialty lab on earth achieves that. Put the remake rate in as an explicit, named assumption and show its sensitivity.
• Treating the cleanroom as a fit-out cost. It is a 9 to 14 month validated-handover milestone that gates every other date in the plan. A timeline showing production three months after funding ends the conversation there.
• Assuming cosmetic or plano lenses escape device regulation. In the United States they do not. A fashion-lens brand carries the same Class II burden as a prescription lens.
• Budgeting one 510(k) for an entire range. Distinct lens families generally need their own submissions and their own listings. Build a submission sequence into the timeline and the budget, with the first one carrying the first revenue.
• Planning a retail or e-commerce channel against the incumbents. Five companies hold 88.7% of North America. Your channel plan should be practitioner-direct, with named target practices and a diagnostic-set placement programme, not shelf space.
• Hiring the lathe operator before the quality lead. Production records created before the quality system exists are unusable in an audit, which means your first six months of output is scrap from a compliance perspective even if the lenses were perfect.

An eighth is less a mistake than a missed opportunity: almost nobody quantifies turnaround time. For a practice managing a frustrated patient, a four-day turnaround against a competitor's eleven days is worth more than a 15% discount. A turnaround commitment belongs in the executive summary, because it is the clearest differentiator a new lab has.

Questions Founders Keep Searching For

How many lenses can one lathe produce in a shift?

For specialty work, plan on 18 to 30 finished lenses per lathe per eight-hour shift once second operations and inspection are counted, not the 60-plus a machine datasheet implies. Setup changes between prescriptions, tool changes and in-process verification all consume machine time. Two lathes across a single shift give you roughly 9,000 to 15,000 lenses of theoretical annual capacity, which sounds enormous against a 2,500-lens break-even until you remember that a 25% remake rate claims a third of it and that demand arrives unevenly. Capacity is rarely the binding constraint in a specialty lab; order flow is.

Do you need an optometrist or optician on staff to run a lens lab?

Not as a licensing requirement in most jurisdictions, because you are manufacturing a device rather than practising clinically. Commercially it is close to essential. Fitting practices call the lab when a lens is not settling, and the person who answers has to discuss limbal clearance and landing-zone alignment credibly. Specialty labs that staff consultation with a qualified contact lens optician run lower remake rates and higher repeat order rates than labs routing those calls to a sales desk. Treat it as a commercial hire with a clinical qualification, and name that person in your management section.

Who actually makes contact lenses for private-label brands?

Mostly contract manufacturers in Taiwan, South Korea and mainland China for stock soft lenses, plus a handful of European and North American houses for specialty work. If your concept is a brand rather than a factory, you are commissioning a contract manufacturer and your plan is a brand and distribution plan. Note that the regulatory obligation usually still lands on whoever places the product on the market under their own name, so the legal-entity structure deserves advice before you write the plan rather than after.

What is the fastest realistic route to first revenue?

Contract lathe work for an established lab. A new lab with a validated room and a qualified process can take overflow or specific geometries from a lab that is capacity-constrained, generating contribution while your own designs work through clearance and while you build a practitioner base. The margin is thinner and the work is not yours to brand, but it converts a dead nine-month validation window into a partially earning one, and it produces the production history an auditor and a lender both want to see.

Sample Business Plan Preview

Here is an extract from a contact lens manufacturing plan written by our team, so you can see the level of specificity a lender expects:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for contact lens manufacturing rather than for generic manufacturing:

• Executive Summary — led by production route, break-even unit volume and the regulatory gate, because that is the order a credit committee reads in
• Company Overview — legal structure, facility location and the founding team's clinical and machining credentials
• Industry Analysis — sourced market sizing, segment concentration and a defensible addressable slice rather than a headline global figure
• Customer Analysis — fitting practices and hospital services profiled by specialty volume, with a named target account list
• Competitor Analysis — the specialty lab field mapped on design depth, turnaround and warranty terms
• Regulatory & Quality Plan — 510(k) or UKCA pathway, submission sequence, ISO 13485 timeline and the cleanroom qualification milestones
• Operations Plan — production flow from order receipt to shipment, named material suppliers with qualified alternates, capacity per lathe shift and the remake handling process
• Marketing Plan — practitioner-direct acquisition, diagnostic-set placement, clinical education and conference presence, with cost per acquired practice
• Management Team — founder bios plus the quality lead, who lenders will look for by name

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis and startup capital requirements, with remake rate and lenses per practice per month built in as adjustable drivers so you can run a lender's sensitivities live in the meeting. If you would rather not write it at all, our business plan writers handle lens manufacturing plans regularly.

Frequently Asked Questions